BioCentury | Sep 15, 2020
Emerging Company Profile

Attralus debuts with $25M series A to tackle systemic amyloidosis

...Inc. (NASDAQ:AKCA) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) are marketed for polyneuropathy associated with hereditary TTR-mediated amyloidosis (hATTR). Vyndaqel...
BioCentury | Feb 18, 2020

Regulatory Roundup: PharmaMar-Jazz, BioCryst products under FDA review; plus EU approvals of Vyndaqel, Beovu; and more

...Eylea aflibercept from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Bayer AG (Xetra:BAYN). The EC also approved Vyndaqel...
BioCentury | Jan 28, 2020
Company News

Bourla chooses BD over buybacks in 2020

...grew 23% to $4.2 billion in 2019, and Xeljanz sales rose 26% to $2.2 billion. Vyndaqel... adults, had total sales of $473 million, with $191 million coming from the U.S. Vyndaqel...
BioCentury | Dec 13, 2019
Company News

Novartis gains CHMP support for Eylea competitor in wet AMD

...for Humira biosimilar Amsparity adalimumab from Pfizer Inc. (NYSE:PFE). CHMP recommended label extensions for Pfizer’s Vyndaqel...
BioCentury | Nov 22, 2019
Company News

Alnylam outlines ambitions, pipeline progress at R&D day

...TTR-targeting amyloidosis franchise beyond Onpattro; if approved in the cardiomyopathy indication, it would compete with Vyndaqel...
BioCentury | Nov 19, 2019
Company News

Nov. 18 Company Quick Takes: Eidos spikes on latest amyloidosis readout; plus Janssen, Pfizer, Tricida, BMS-Celgene

...similar time point in the Phase III ATTR-ACT study, which led to the approval of Vyndaqel...
BioCentury | Oct 30, 2019
Financial News

Pfizer surprises Street with Vyndaqel sales, uptake

...Uptake of Pfizer's Vyndaqel tafamidis in 3Q19 surpassed a consensus estimate following its approval in May...
...touted as a potential blockbuster to treat transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Pfizer Inc. (NYSE:PFE) said Vyndaqel...
...Vyndamax as a more convenient formulation than Vyndaqel, which is administered via four pills daily. Vyndaqel...
BioCentury | Oct 5, 2019

Seeking bright spots in 4Q19 amid continued underperformance

...could show how the TTR stabilizer would compete against Vyndaqel tafamidis meglumine from Pfizer Inc. (NYSE:PFE). Vyndaqel...
BioCentury | Sep 24, 2019
Company News

Unexpected shakeup at Akcea comes amid drug launches

...U.S.: Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and Vyndaqel/Vyndamax tafamidis from Pfizer Inc. (NYSE:PFE). Vyndaqel...
BioCentury | Jun 29, 2019

Biotech backs down in 2Q19

...breast cancer Pfizer Inc. (NYSE:PFE) Gained in acquisition of FoldRx Pharmaceuticals Inc. FDA approves Vyndaqel tafamidis meglumine...
Items per page:
1 - 10 of 67